YF-VAX yellow fever
Selected indexed studies
- Yellow Fever Vaccine. (, 2006) [PMID:30000198]
- Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees. (Viruses, 2020) [PMID:33198381]
- Incidence of anaphylaxis to YF-VAX® yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999-2018. (J Travel Med, 2024) [PMID:38051650]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vaccines for travelers. (2018) pubmed
- Yellow Fever Vaccine. (2006) pubmed
- Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models. (2021) pubmed
- Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees. (2020) pubmed
- Incidence of anaphylaxis to YF-VAX® yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999-2018. (2024) pubmed
- Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. (2005) pubmed
- Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. (2002) pubmed
- Characterization of "Off-Target" Immune Modulation Induced by Live Attenuated Yellow Fever Vaccine. (2024) pubmed
- Yellow Fever Vaccine Administration at Global TravEpiNet (GTEN) Clinics during a Period of Limited Vaccine Availability in the United States, 2017-2018. (2021) pubmed
- Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial. (2024) pubmed